Combined radiotherapy and immunotherapy in urothelial bladder cancer: harnessing the full potential of the anti-tumor immune response

M Daro-Faye, W Kassouf, L Souhami, G Marcq… - World journal of …, 2021 - Springer
Purpose Radiotherapy (RT), as part of trimodal therapy, is an attractive alternative treatment
in patients with urothelial muscle-invasive bladder cancer (MIBC). There is accumulating …

Implications of oncology trial design and uncertainties in efficacy-safety data on health technology assessments

D Trapani, K Tay-Teo, ME Tesch, F Roitberg… - Current …, 2022 - mdpi.com
Background: Advances in cancer medicines have resulted in tangible health impacts, but the
magnitude of benefits of approved cancer medicines could vary greatly. Health Technology …

[HTML][HTML] Myeloid-derived suppressor cells are essential partners for immune checkpoint inhibitors in the treatment of cisplatin-resistant bladder cancer

Y Takeyama, M Kato, S Tamada, Y Azuma, Y Shimizu… - Cancer Letters, 2020 - Elsevier
Myeloid-derived suppressor cells (MDSCs) are one of the key players that contribute to
immune evasion. The purpose of the present study was to investigate whether MDSCs could …

Tumor-derived CC motif ligand 2 induces the recruitment and polarization of tumor-associated macrophages and increases the metastatic potential of bladder cancer …

Y Chiang, YC Tsai, CC Wang, FJ Hsueh… - International Journal of …, 2022 - Elsevier
Purpose Radiation therapy (RT) is mainly used for bladder preservation in patients with
muscle-invasive bladder cancer. The response of urothelial tumors to RT remains …

Current perspectives on immunotherapy in the peri-operative setting of muscle-infiltrating bladder cancer

PA Zucali, N Cordua, F D'Antonio, F Borea… - Frontiers in …, 2020 - frontiersin.org
Patients with muscle-infiltrating bladder cancer (MIBC) present a high risk of postoperative
recurrence and death from metastatic urothelial cancer despite surgical resection. Before the …

Engineering nanoparticles for cancer immunotherapy: Current achievements, key considerations and future perspectives

MU Farooq, CH Lawrie, NN Deng - Chemical Engineering Journal, 2024 - Elsevier
Cancer immunotherapies, which rely on training or stimulating our immune system, are
revolutionizing the way of cancer treatment. In recent years, these revolutionary weapons …

Advances in transversal topics applicable to the care of bladder cancer patients in the real-world setting

M Garrido Siles, A López-Beltran, P Pelechano… - Cancers, 2022 - mdpi.com
Simple Summary There are a number of scientific questions that are novel or controversial,
which are clinically relevant in the real-world setting for patients diagnosed with bladder …

From clinical trials to clinical use of checkpoint inhibitors for patients with metastatic urothelial cancer

R Tambaro, MD Napoli, C Pisano, SC Cecere… - …, 2021 - Taylor & Francis
Monoclonal antibodies targeting the checkpoint inhibitors (CPIs), programmed cell death
protein-1 or programmed cell death ligand-1, are changing the landscape of urothelial …

Value of biomarker expression for randomized clinical trial design: One (more) missed opportunity

FE Vera-Badillo, AJ Robinson… - Journal of clinical …, 2020 - pubmed.ncbi.nlm.nih.gov
Value of Biomarker Expression for Randomized Clinical Trial Design: One (More) Missed
Opportunity Value of Biomarker Expression for Randomized Clinical Trial Design: One (More) …